Trade names Eucrisa Legal status US: ℞-only PubChem CID 44591583 Molar mass 251.0451 g/mol | CAS Number 906673-24-3 DrugBank DB05219 | |
 | ||
Crisaborole (INN, USAN, trade name Eucrisa ew-KRIS-ə, codenamed AN2728) is a non-steroidal, topical medication approved for the treatment of mild-to-moderate atopic dermatitis (eczema) in patients 2 years of age and older. As of 2016 it is also under development by Anacor Pharmaceuticals for the topical treatment of psoriasis.
Contents
Mechanism of action
It is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. Chemically, crisaborole is a phenoxybenoxaborole. It contains a boron atom that helps penetrate the skin and is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.
Clinical trials
As of 2016, two Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis have been completed, and some Phase II trials had been completed for the treatment of psoriasis.